169 related articles for article (PubMed ID: 7521238)
1. Prognostic value of immunophenotypic characteristics of blast cells in acute myeloid leukemia.
Lanza F; Rigolin GM; Moretti S; Latorraca A; Castoldi G
Leuk Lymphoma; 1994; 13 Suppl 1():81-5. PubMed ID: 7521238
[TBL] [Abstract][Full Text] [Related]
2. CD34+/CD33+ blast cells: correlation with FAB subtypes.
Rigolin GM; Lanza F; Ferrari L; Castoldi G
Leuk Lymphoma; 1995; 18 Suppl 1():43-8. PubMed ID: 7496354
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
[TBL] [Abstract][Full Text] [Related]
4. Surface markers in adult acute myeloblastic leukemia: correlation of CD19+, CD34+ and CD14+/DR--phenotypes with shorter survival. Groupe d'Etude Immunologique des Leucémies (GEIL).
Solary E; Casasnovas RO; Campos L; Béné MC; Faure G; Maingon P; Falkenrodt A; Lenormand B; Genetet N
Leukemia; 1992 May; 6(5):393-9. PubMed ID: 1375696
[TBL] [Abstract][Full Text] [Related]
5. [The immunophenotypic and clinical characteristics of NPM1 mutated acute myeloid leukemia patients].
Liu YR; Chang Y; Ruan GR; Qin YZ; Lai YY; Shi HX; Wang YZ; Li LD; Jiang B; Li JL
Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):98-103. PubMed ID: 23611213
[TBL] [Abstract][Full Text] [Related]
6. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
Pituch-Noworolska A
Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
[TBL] [Abstract][Full Text] [Related]
7. [Immunologic characteristics and prognosis of acute myeloid leukemia M1].
Zhao F; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):687-91. PubMed ID: 17708783
[TBL] [Abstract][Full Text] [Related]
8. Role of blast cell immunophenotyping for the diagnosis and prognosis of acute myeloid leukemia.
Dubosc-Marchenay N; Lacombe F; Dumain P; Marit G; Montastruc M; Belloc F; Reiffers J
Hematol Oncol; 1992; 10(5):235-49. PubMed ID: 1493908
[TBL] [Abstract][Full Text] [Related]
9. Myeloid enzymes profile related to the immunophenotypic characteristics of blast cells from patients with acute myeloid leukemia (AML) at diagnosis.
Klobusicka M; Kusenda J; Babusikova O
Neoplasma; 2005; 52(3):211-8. PubMed ID: 15875082
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometry measurement of GM-CSF receptors in acute leukemic blasts, and normal hemopoietic cells.
Lanza F; Castagnari B; Rigolin G; Moretti S; Latorraca A; Ferrari L; Bardi A; Castoldi G
Leukemia; 1997 Oct; 11(10):1700-10. PubMed ID: 9324292
[TBL] [Abstract][Full Text] [Related]
11. [Immunophenotype characteristics and prognosis of acute leukemia patients with cross expressing lymphoid and myeloid lineage associated antigens].
Jiang NG; Chen XM; Zhu HL; Zhong L; Zeng TT; Jia YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1405-9. PubMed ID: 21176339
[TBL] [Abstract][Full Text] [Related]
12. Acute myeloid leukemia with t(6;9) (p23;q34): association with myelodysplasia, basophilia, and initial CD34 negative immunophenotype.
Alsabeh R; Brynes RK; Slovak ML; Arber DA
Am J Clin Pathol; 1997 Apr; 107(4):430-7. PubMed ID: 9124211
[TBL] [Abstract][Full Text] [Related]
13. Incidence and prognostic relevance of CD34 expression in acute myeloblastic leukemia: analysis of 141 cases.
Raspadori D; Lauria F; Ventura MA; Rondelli D; Visani G; de Vivo A; Tura S
Leuk Res; 1997 Jul; 21(7):603-7. PubMed ID: 9301680
[TBL] [Abstract][Full Text] [Related]
14. The immunophenotype of minimally differentiated acute myeloid leukemia (AML-M0): reduced immunogenicity and high frequency of CD34+/CD38- leukemic progenitors.
Costello R; Mallet F; Chambost H; Sainty D; Arnoulet C; Gastaut JA; Olive D
Leukemia; 1999 Oct; 13(10):1513-8. PubMed ID: 10516751
[TBL] [Abstract][Full Text] [Related]
15. The presence of lymphoid-associated antigens in adult acute myeloid leukemia is devoid of prognostic relevance.
Lauria F; Raspadori D; Ventura MA; Rondelli D; Testoni N; Tosi P; Michieli M; Damiani D; Motta MR; Tura S
Stem Cells; 1995 Jul; 13(4):428-34. PubMed ID: 7549902
[TBL] [Abstract][Full Text] [Related]
16. [Immunophenotypic features of acute myeloid leukemia with AML-1/ETO fusion gene].
Zhang JJ; DU X; Huang ZX; Su JH; Zhou MH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr; 15(2):378-81. PubMed ID: 17493351
[TBL] [Abstract][Full Text] [Related]
17. [Screening and structure analysis of nucleic acid aptamers binding to surface of CD33(+)/CD34(+) cells from patients with acute myeloid leukemia subtype M₂].
Zhang SQ; Wang GP; Zhu P; Liang JJ; Xu YJ; Peng MY; Chen Y; Tan SQ; Chen FP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Jun; 19(3):561-5. PubMed ID: 21729522
[TBL] [Abstract][Full Text] [Related]
18. [Multidrug resistance in acute leukemia].
Takeshita A; Ohno R
Rinsho Ketsueki; 1996 Aug; 37(8):640-6. PubMed ID: 8827870
[TBL] [Abstract][Full Text] [Related]
19. CD7 expression in acute myeloid leukemia.
Del Poeta G; Stasi R; Venditti A; Cox C; Aronica G; Masi M; Bruno A; Simone MD; Buccisano F; Papa G
Leuk Lymphoma; 1995 Mar; 17(1-2):111-9. PubMed ID: 7539657
[TBL] [Abstract][Full Text] [Related]
20. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361).
Baer MR; Stewart CC; Dodge RK; Leget G; Sulé N; Mrózek K; Schiffer CA; Powell BL; Kolitz JE; Moore JO; Stone RM; Davey FR; Carroll AJ; Larson RA; Bloomfield CD
Blood; 2001 Jun; 97(11):3574-80. PubMed ID: 11369653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]